A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/17/2019 |
| Start Date: | March 2013 |
| End Date: | June 2015 |
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Purpose of this phase I/II study is to test how well LY2090314 works in combination with
different chemotherapies in treating participants with metastatic pancreatic cancer.
different chemotherapies in treating participants with metastatic pancreatic cancer.
Inclusion Criteria:
- Metastatic pancreatic cancer with metastases amenable to biopsy
- Willingness to provide tissue and blood samples for research purposes
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
Exclusion Criteria:
- History of islet cell, acinar cell, or cystadenocarcinomas
- Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or
FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)
- Radiation therapy, immunotherapy or biologic therapy <28 days prior to study entry
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials